Peripheral osimertinib (osi) plasma trough concentration (Cmin,SS) as surrogate parameter for development and progression of brain metastasis (BM) in patients (pts) with EGFR plus advanced non-small cell lung cancer (aNSCLC)-MedSci.cn

Peripheral osimertinib (osi) plasma trough concentration (Cmin,SS) as surrogate parameter for development and progression of brain metastasis (BM) in patients (pts) with EGFR plus advanced non-small cell lung cancer (aNSCLC)

Gulikers, JL; Veerman, MGD; Jebbink, M; Kruithof, P; Steendam, CMJ; Boosman, R; Mathijssen, RH; Tjan-Heijnen, V; Driessen, A; Dursun, S; Smit, EF; Dingemans, AMC; van Geel, R; Croes, S; Hendriks, L

ANNALS OF ONCOLOGY, 2023; 34 ():

科室
- - 订阅+
  - 更多科室
工具
服务